


RECEIVED

MAY 08 2002

TECH CENTER 1600/2900



#12/B
5/14/02
PATENT
ATTORNEY DOCKET
NO. 69176
Style

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Biedermann et al.)

Serial No.: 09/596,001)

Filed: June 16, 2000)

Title: NEW PIPERAZINYL-
SUBSTITUTED
PYRIDYLALKANE, ALKENE AND
ALKINE CARBOXAMIDES)

Group Art Unit: 1624)

Examiner: T. Truong)

CERTIFICATE OF MAILING

I hereby certify that this
paper is being deposited with
the United States Postal
Service with sufficient
postage as first class mail
in an envelope addressed to:
Commissioner of Patents and
Trademarks, Washington, D.C.
20231, on this date.

MAY 01 2002

Date James P. Krueger
Registration No. 35,234
Attorney for
Applicant(s)

Amendment A

Honorable Commissioner of Patents
and Trademarks
ATTENTION: Assistant Commissioner
for Patents
Washington, D.C. 20231

Dear Sir:

In response to the office action dated November 1, 2001,
please amend the above-identified application as follows.

IN THE CLAIMS:

Please cancel claims 1, 9-11, 13, 15-23, and 25-31.

2. (Once amended) ~~Pyridylalkane~~, pyridylalkene and
pyridylalkine carboxamides of formula (I)

B1
2001
05/08/2002 NH0HAMH1 00000027 061135 09596001

01 FC:102 840.00 CH

from phenyl, pyridyl or naphthyl,

~~BSF~~
G⁵ is -COR¹⁶

Sub
E7 R¹⁶ is selected from the group consisting of
trifluoromethyl, C₁-C₆-alkoxy, C₃-C₆-alkenyloxy, and benzyloxy.

50. The pharmaceutical composition according to claim 12, wherein the pharmaceutical composition is present in a solid, peroral administrable form as a tablet, capsule, coated tablet, or as a liquid, peroral administration solution, suspension, effervescent tablet, in the form of tabs or sachets, which may be in the form of a suitable injection or infusion preparation together with suitable pharmaceutically acceptable carriers and adjuvants, in the form of a concentrate, powder or lyophilisate, in the form of a gastrointestinal therapeutic system (GITS) for systemic treatment, in the form of a salve, suspension, emulsion, a balm or plaster or in the form of an externally applicable solution, in the form of a rectal, genital, or transurethral administration emulsion, a solution, a liposomal solution, an implant, suppository or a capsule, or in the form of a composition capable of being applied nasally.

REMARKS

Upon entry of the present amendment, claims 2-8, 12, 14, and 24 have been amended, claims 1, 9-11, 13, 15-23, and 25-31 have been canceled, claims 32-50 have been added, and claims 2-8, 12, 14, 24, and 32-50 are pending. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made".